Dr Reddy's Laboratories is delaying commercial supplies of its semaglutide product after certain batches failed quality specifications. The Indian drugmaker says it's investigating the root cause but insists there's no patient safety risk. The news sent its shares down 1.8%, even as broader pharma indices climbed.
Dr Reddy's Laboratories has hit a speed bump in its push into the booming obesity and diabetes drug market. The Indian pharmaceutical giant announced it is temporarily delaying commercial supplies of semaglutide — the active ingredient in Novo Nordisk's blockbuster Ozempic and Wegovy — after certain batches were found to be out of specification. Dr Reddy's had already launched its own semaglutide injection, branded as Obeda, in India for diabetes treatment.
The company says it is investigating the root cause of the quality issue and taking corrective measures, while stressing that patient safety is not at risk and that existing global regulatory filings remain unaffected. No timeline for resolving the supply disruption was provided.
Key Takeaways:
Why it matters: As generic semaglutide competition heats up globally, supply reliability and manufacturing quality will be key differentiators. This setback underscores the challenges generic makers face in scaling up production of complex molecules like semaglutide.
